Immunome Inc. (IMNM.us)今日盘中大涨6.09%,引发了市场的广泛关注。
根据新闻报导,该公司是一家生物制药公司,致力于利用专有的人体记忆B细胞平台发现和开发一流的抗体疗法。报导称,该公司的目标是建立广泛的临床前和临床资产管道,重点领域包括肿瘤学和传染病如COVID-19。
分析指出,作为一家前景看好的生物技术公司,Immunome正在开发多个有潜力的在研管线药物,如IM-1021和IM-4320。机构方面,所有7家参与评级的机构均给予该股买入评级,体现了市场对该公司长期增长前景的看好。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.